Defence Therapeutics Inc.
DTCFF
$0.39
$0.0411.57%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -95.80% | -113.83% | 39.04% | 4.60% | -52.64% |
| Total Depreciation and Amortization | 1.49% | -43.22% | -15.11% | 13.01% | -3.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 740.07% | 6.09% | -22.44% | -61.66% | 141.94% |
| Change in Net Operating Assets | -254.06% | 60.20% | -405.12% | 105.36% | -840.96% |
| Cash from Operations | -13.81% | -91.93% | 12.08% | 57.21% | -191.25% |
| Capital Expenditure | -100.00% | 128.10% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | 128.10% | -41.67% | -- | -100.00% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -357.58% | 85.33% | 82.63% |
| Issuance of Common Stock | 12,831.65% | -- | -- | -100.00% | 426.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 99.63% | -2,220.29% | 97.21% | -1,056.07% |
| Cash from Financing | 13,156.92% | -98.53% | 18,004.05% | -100.27% | 492.80% |
| Foreign Exchange rate Adjustments | 100.00% | -222.50% | 344.44% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 246.37% | -224.67% | 229.05% | -145.09% | 271,720.00% |